ArticleAmerican journal of translational research2025
TNXB modulates radiosensitivity of esophageal cancer through the ATM/P53 pathway.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEsophageal carcinoma (ESCA) is a common malignancy, and modulating radiosensitivity is crucial for individualized treatment. Tenascin XB (TNXB) overexpression in tumors is speculated to influence radiosensitivity. This study aims to investigate whether TNXB overexpression prior to irradiation sensitizes human ESCA cells
methodsThe expression of TNXB in tumor specimens was examined using Real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry. The relationships between TNXB expression and clinicopathological characteristics were analyzed. Two human ESCA cell lines (TE-1 and OE33) were subjected to explore the effect of TNXB expression on radiosensitivity. DNA damage, apoptosis, cell cycle arrest, and protein expression were assessed by colony formation assay, western blotting and flow cytometry, respectively.
resultsTNXB displayed a low expression in tumor tissues. Reduced TNXB expression was significantly correlated with larger tumor size and higher TNM stage. TNXB overexpression coupled with X-ray irradiation markedly suppressed colony formation in TE-1 and OE33 cells, and increased γH2AX expression, apoptosis rate, and promoted cell cycle arrest. Additionally, the combined treatment of TNXB overexpression and X-ray irradiation resulted in upregulation and phosphorylation of Ataxia Telangiectasia Mutated (ATM) and P53, leading to elevated cleaved-caspase3 and decreased pro-caspase3 levels. si-ATM treatment reversed these effects.
conclusionOur findings demonstrate that TNXB enhances radiosensitivity in TE-1 and TE-10 cells by the ATM/P53 pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.